论文部分内容阅读
目的探讨联合应用阿托伐他汀和阿昔莫司治疗混合性高脂血症的临床疗效。方法共入选186例混合性高脂血症患者,随机分入阿托伐他汀组(n=52)、阿昔莫司组(n=54)和联合治疗组(阿托伐他汀+阿昔莫司,n=80)。观察治疗前后主要血脂参数的变化幅度以及不良反应。结果联合治疗组血脂参数变化幅度最显著,血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)和甘油三酯(TG)均显著下降,而血清高密度脂蛋白胆固醇(HDLC)升高优于阿托伐他汀组和阿昔莫司组(P<0.01)。结论阿昔莫司组与小剂量阿托伐他汀联合治疗可全面调节血脂,有效治疗混合型高脂血症。
Objective To investigate the clinical efficacy of combination of atorvastatin and acipimox in the treatment of mixed hyperlipidemia. Methods A total of 186 patients with mixed hyperlipidemia were randomized into atorvastatin group (n = 52), acipimox (n = 54) and combination therapy group (atorvastatin + acipimox Division, n = 80). Observed before and after treatment, changes in the main lipid parameters and adverse reactions. Results In the combination therapy group, the changes of blood lipid parameters were the most significant. The levels of serum total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) and triglyceride (TG) were significantly decreased, while the serum levels of high density lipoprotein cholesterol Higher than the atorvastatin group and the acipimox group (P <0.01). Conclusion Combination of acipimox and low-dose atorvastatin can fully regulate blood lipids and effectively treat mixed hyperlipidemia.